Economic modeling of the value of rapid diagnostics
Dear All (and again with thanks to Arjun Srinivasan for co-authoring this pair of newsletters): In parallel with the newsletter discussing a recent paper on
27 May 2026
No Comments
R&D Insight
BARDA seeks info on Phase 2+ antifungals for Candida and Aspergillus
Dear All: As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for a variety of possible threats.
22 May 2026
No Comments
In Praise of Non-Inferiority
Dear All (wonkish but intended for everybody to read and absorb): 27 Jan 2021 update: This topic now has its own YouTube video! As the
19 September 2020
No Comments
The language of AMR: The power of metaphor
Dear All, Acronyms and jargon fill our daily scientific lives but can be impenetrable to newcomers. A great example is the title of the 20 Feb
7 April 2026
No Comments
Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery
Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call is that the resistance arises
19 April 2026
No Comments
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct is due to Patricia and
16 April 2026
No Comments
EMA: “Regulatory sandboxes” to explore approval pathways
Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating
12 March 2026
No Comments
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Note: See also these related newsletters: 20 Feb 2020 (link) on DTR as part of the language of resistance and 7 June 2020 (link) on
13 January 2019
No Comments
GO-Dx: Global One Health Diagnostics Access Compact
Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, it really has been 10
9 April 2026
No Comments
FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval
Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for co-authoring this newsletter), In a
1 March 2026
No Comments